Terren Peizer

Terren Scott Peizer, is an investor and company executive. He is the CEO of Acuitas Group Holdings and Neurmedix.[1] He is also the CEO and chairman of Ontrak.[2] He has held senior executive positions within technology and biotech companies, at Goldman Sachs and First Boston,[1] and as a bond salesman at Drexel Burnham Lambert.[3][4]

Terren Scott Peizer
Born (1959-07-31) July 31, 1959
Beachwood, Ohio
Alma materWharton School of the University of Pennsylvania
OccupationFinancier
Websitewww.terrenpeizer.com

Early life and education

Peizer's hometown is Beachwood, Ohio.[5] Peizer graduated from the Wharton School of the University of Pennsylvania.[1]

Career

In 1983, Peizer worked at Goldman Sachs[1] and later worked at First Boston as a salesman. Michael Milken hired Peizer as a bond salesman at Drexel Burnham Lambert in 1985.[6] He was the manager of David M. Solomon's account with Drexel[5] and given a 3.5 million dollar salary and a $500.000 loan to invest in the partnership.[7] Peizer worked directly under (and at the same desk as) Milken and admired him, sometimes pretending to be him on the phone, and calling him "Dad".[8] When investigations into Milken's illegal activities started, Peizer agreed to provide material evidence to prosecutors in exchange for immunity.[9]

In 1989 Peizer purchased the Omaha Racers, a minor league basketball team.[10] In 1991 he bought UTI Chemicals Inc. through his company Financial Group Holdings Inc.[11] and stepped down as its chairman in 1994.[12]

In 1993 he was elected Chairman at CMS Enhancements after acquiring a 36.8% share of the company.[13] From 1997 to 1999, Peizer was president of Hollis-Eden, a pharmaceutical company.[14][15] In 1999 Peizer raised money for Tera Computer Company, a manufacturer of supercomputers, which allowed them to later buy out Cray Research and became its chairman and a director.[16] He stepped back down as chairman in 2000 because the company was concerned that he would not obtain a security clearance from the United States Department of Defense by the end of 2000 to transfer Cray's classified business from Silicon Graphics, causing Cray Research to pay a penalty fee to Silicon Graphics.[17]

Peizer founded Hythiam Inc., a pharmaceutical company, in 2004.[18] The firm bought the rights to Juan Jose Legarda's addiction treatment pharmaceuticals.[19] 60 Minutes and The Dallas Morning News criticized Peizer after the company bypassed clinical studies and government approval when bringing Prometa to market.[20][21]

In 2018, Peizer became CEO and director of BioVie, a pharmaceutical company.[22]

References
  1. "Catasys Inc (CATS.OQ)". Reuters. Retrieved 2020-11-25.
  2. Hackett, Mallory (2020-11-03). "Ontrak deepens its behavioral health platform with LifeDojo acquisition". MobiHealthNews. Retrieved 2020-11-25.
  3. Labaton, Stephen (1988-12-10). "4th Drexel Employee in Immunity Bargain". The New York Times. ISSN 0362-4331. Retrieved 2020-11-25.
  4. "Kohlberg, Kravis Official Tells of a Hidden Milken Stake". The New York Times.
  5. Lee, Patrick (1994-07-31). "In the Shadow of the '80s : Yesterday's High Rollers Struggle in a New Era of Sobriety". Los Angeles Times. Retrieved 2020-11-26.
  6. "No Sales, but Watch the Stock Soar". The New York Times.
  7. Kornbluth, Jesse. Highly confident: The Crime and Punishment of Michael Milken. p. 213.
  8. Griffin, Nancy; Masters, Kim (12 January 2016). Hit & Run: How Jon Peters and Peter Guber Took Sony for a Ride in Hollywood. ISBN 9781439128046.
  9. "4th Drexel Employee in Immunity Bargain". The New York Times.
  10. "Omaha CBA team sold to Los Angeles banker". The Lincoln Star. 7 September 1989. p. 18. Retrieved 11 August 2020.
  11. Michaud, Anne (1991-04-10). "Drexel Figure Gains Control of UTI Chemicals". Los Angeles Times. Retrieved 2020-11-25.
  12. "Jim Orefice has been appointed chairman..." Los Angeles Times. 1994-02-07. Retrieved 2020-11-26.
  13. "CMS Enhancements Names New Top Management Team". LA Times.
  14. "Market Place; No Sales, but Watch the Stock Soar". The New York Times.
  15. "Small world, ain't it?". Forbes. 1999-09-05. Retrieved 2020-11-25.
  16. "L.A. Financier Reemerges as Key Player in Cray Deal". Los Angeles Business Journal.
  17. "Technology Briefs". Wall Street Journal. 2000-12-26. ISSN 0099-9660. Retrieved 2020-11-25.
  18. Bartholomew, Dana (7 December 2018). "Catasys Thrives on Data Dives". Los Angeles Business Journal. Retrieved 12 August 2020.
  19. Alpert, Bill. "Curb Your Cravings For This Stock". Barrons. Retrieved 2020-11-26.
  20. "Prescription For Addiction". 60 Minutes. CBS News. December 9, 2007. Archived from the original on 2020-08-05. Retrieved 2008-08-22.
  21. Ramshaw, Emily (January 20, 2008). "Texas' Prometa program for treating meth addicts draws skeptics". Dallas Morning News. Archived from the original on 2020-08-05.
  22. Iral, Vince (2018-07-04). "BioVie sells stock, warrants to Acuitas, names CEO". S&P Global. Retrieved 2020-11-25.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.